Comparative biochemical evaluation reveals differences in small-molecule inhibitor efficacy on CDK/Cyclin in different mammals, highlighting the need for appropriate model systems.
Key Points
The study aims to compare the effectiveness of small-molecule inhibitors targeting CDK/Cyclin complexes across various mammalian species, particularly focusing on their inhibitory potency.
Biochemical screening assays were employed to evaluate small-molecule inhibitors on CDK/Cyclin complexes.
Late-stage development or approved CDK inhibitors were tested for their efficacy against human, rat, mouse, dog, and primate CDK/Cyclin complexes.
The primary focus was on CDK4/CycD1 and comparisons of inhibitor potency were made among species.
Notable differences in inhibitory potency were observed, with palbociclib showing a ten-fold variance in inhibition between human and murine CDK4/CycD1.
These findings suggest that biochemical evaluations from different species can influence the choice of models for drug development.
The study emphasizes the importance of early screenings in predicting potential drug efficacy and safety.